166 related articles for article (PubMed ID: 38688611)
1. Targeting Methionine Addiction Combined With Low-dose Irinotecan Arrested Colon Cancer in Contrast to High-dose Irinotecan Alone, Which Was Ineffective, in a Nude-mouse Model.
Sato M; Mizuta K; Han Q; Morinaga S; Kang BM; Kubota Y; Mori R; Baranov A; Kobayashi K; Ardjmand D; Kobayashi N; Bouvet M; Ichikawa Y; Nakajima A; Hoffman RM
In Vivo; 2024; 38(3):1058-1063. PubMed ID: 38688611
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Methioninase Decreased the Effective Dose of Irinotecan by 15-fold Against Colon Cancer Cells: A Strategy for Effective Low-toxicity Treatment of Colon Cancer.
Sato M; Han Q; Kubota Y; Baranov A; Ardjmand D; Mizuta K; Morinaga S; Kang BM; Kobayashi N; Bouvet M; Ichikawa Y; Nakajima A; Hoffman RM
Anticancer Res; 2024 Jan; 44(1):31-35. PubMed ID: 38159986
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice.
Tan Y; Sun X; Xu M; Tan X; Sasson A; Rashidi B; Han Q; Tan X; Wang X; An Z; Sun FX; Hoffman RM
Clin Cancer Res; 1999 Aug; 5(8):2157-63. PubMed ID: 10473100
[TBL] [Abstract][Full Text] [Related]
4. Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis.
Kim MJ; Han Q; Bouvet M; Hoffman RM; Park JH
Anticancer Res; 2023 Jan; 43(1):19-24. PubMed ID: 36585181
[TBL] [Abstract][Full Text] [Related]
5. Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.
Sato M; Han Q; Mori R; Mizuta K; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
Anticancer Res; 2024 Apr; 44(4):1499-1504. PubMed ID: 38538002
[TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
7. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM
Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758
[TBL] [Abstract][Full Text] [Related]
8. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871
[TBL] [Abstract][Full Text] [Related]
9. Selective Synergy of Rapamycin Combined With Methioninase on Cancer Cells Compared to Normal Cells.
Ardjmand D; Kubota Y; Sato M; Han Q; Mizuta K; Morinaga S; Hoffman RM
Anticancer Res; 2024 Mar; 44(3):929-933. PubMed ID: 38423628
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
Riviere K; Kieler-Ferguson HM; Jerger K; Szoka FC
J Control Release; 2011 Aug; 153(3):288-96. PubMed ID: 21600250
[TBL] [Abstract][Full Text] [Related]
11. Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T; Li S; Han Q; Tan Y; Kiyuna T; Igarashi K; Kawaguchi K; Hwang HK; Miyake K; Singh AS; Nelson SD; Dry SM; Li Y; Hiroshima Y; Lwin TM; DeLong JC; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
Oncotarget; 2017 May; 8(22):35630-35638. PubMed ID: 28404944
[TBL] [Abstract][Full Text] [Related]
12. Oral-recombinant Methioninase in Combination With Rapamycin Eradicates Osteosarcoma of the Breast in a Patient-derived Orthotopic Xenograft Mouse Model.
Masaki N; Han Q; Samonte C; Wu NF; Hozumi C; Wu J; Obara K; Kubota Y; Aoki Y; Bouvet M; Hoffman RM
Anticancer Res; 2022 Nov; 42(11):5217-5222. PubMed ID: 36288875
[TBL] [Abstract][Full Text] [Related]
13. Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Sugisawa N; Higuchi T; Han Q; Hozumi C; Yamamoto J; Tashiro Y; Nishino H; Kawaguchi K; Bouvet M; Murata T; Unno M; Hoffman RM
Cancer Chemother Pharmacol; 2021 Jul; 88(1):61-67. PubMed ID: 33768300
[TBL] [Abstract][Full Text] [Related]
14. A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model.
Kiyuna T; Tome Y; Murakami T; Miyake K; Igarashi K; Kawaguchi K; Oshiro H; Higuchi T; Miyake M; Sugisawa N; Zhang Z; Razmjooei S; Wangsiricharoen S; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Eckardt MA; Singh AS; Chawla S; Kanaya F; Eilber FC; Singh SR; Zhao M; Hoffman RM
Biochem Biophys Res Commun; 2018 Nov; 505(3):733-739. PubMed ID: 30292411
[TBL] [Abstract][Full Text] [Related]
15. Oral Installation of Recombinant Methioninase-producing
Kubota Y; Han Q; Hamada K; Aoki Y; Masaki N; Obara K; Baranov A; Bouvet M; Tsunoda T; Hoffman RM
Cancer Genomics Proteomics; 2022; 19(6):683-691. PubMed ID: 36316039
[TBL] [Abstract][Full Text] [Related]
16. Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease.
Kubota Y; Han Q; Hozumi C; Masaki N; Yamamoto J; Aoki Y; Tsunoda T; Hoffman RM
Anticancer Res; 2022 May; 42(5):2567-2572. PubMed ID: 35489727
[TBL] [Abstract][Full Text] [Related]
17. Green tea catechins in combination with irinotecan attenuates tumorigenesis and treatment-associated toxicity in an inflammation-associated colon cancer mice model.
Borah G; Bharali MK
J Egypt Natl Canc Inst; 2021 Jul; 33(1):17. PubMed ID: 34308509
[TBL] [Abstract][Full Text] [Related]
18. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
Pencreach E; Guérin E; Nicolet C; Lelong-Rebel I; Voegeli AC; Oudet P; Larsen AK; Gaub MP; Guenot D
Clin Cancer Res; 2009 Feb; 15(4):1297-307. PubMed ID: 19190131
[TBL] [Abstract][Full Text] [Related]
19. Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model.
Park JH; Han Q; Zhao M; Tan Y; Higuchi T; Yoon SN; Sugisawa N; Yamamoto J; Bouvet M; Clary B; Singh SR; Hoffman RM
Tissue Cell; 2019 Dec; 61():109-114. PubMed ID: 31759402
[TBL] [Abstract][Full Text] [Related]
20. Effective Metabolic Targeting of Human Osteosarcoma Cells
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Murakami T; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Hoffman RM
Anticancer Res; 2017 Sep; 37(9):4807-4812. PubMed ID: 28870899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
